In a research report issued today, Wedbush analyst Liana Moussatos reiterated an Outperform rating on Intercept Pharmaceuticals Inc (NASDAQ:ICPT), with a price target of $493, following the …
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat …
Intercept Pharmaceuticals Inc (NASDAQ:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic …
Out of all of the stocks in the Healthcare sector, biopharmaceutical stocks are some of the most popular due to the revenue potential …
The latest in the onslaught of biotech initial public offerings, Spark Therapeutics (ONCE) priced at $23 on Thursday evening. Twelve hours later, the stock opened at …
In a research report published Friday, Wedbush analyst Liana Moussatos reiterated an Outperform rating on Intercept Pharmaceuticals (NASDAQ:ICPT) with a price target of …
In a research report released Friday, Deutsche Bank analyst Alethia Young maintained a Buy rating on Intercept Pharma (NASDAQ:ICPT) with a price target …
Cowen’s healthcare analyst Ritu Baral is weighing in with her thoughts on Intercept Pharmaceuticals (NASDAQ:ICPT), following the news that the company’s investigational product obeticholic acid (OCA) …
In a research report sent to investors, Oppenheimer analyst Akiva Felt reiterated an Outperform rating on Intercept Pharmaceuticals (NASDAQ:ICPT) with a price target …
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), today announced that its investigational product obeticholic acid (OCA) has received “breakthrough therapy designation” from the U.
